## JBL: Jabil Inc. - XLK: Technology

### Executive Summary

No thesis match: MRS_10 1.9% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($210.30)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Jabil sells two St. Petersburg buildings for $25M in leaseback deal**
- Source: The Business Journals | 20251222T182727 | Neutral | Relevance: 100%
- Jabil, an electronics manufacturer, has sold two St. Petersburg buildings for $25 million in a leaseback deal. This move comes as the company plans to invest heavily in a new manufacturing facility in North Carolina. Jabil will continue to occupy the buildings, securing their operations in St. Petersburg while expanding elsewhere.

**2. Jabil opens medical device lab to foster innovation**
- Source: St Pete Catalyst | 20251222T173906 | Bullish | Relevance: 100%
- Jabil Inc. has opened a new Advanced Catheter Development Lab at its St. Petersburg headquarters, aiming to position the city as a center for innovation in minimally invasive medical devices. This lab, developed in collaboration with the University of Florida and the University of South Florida, offers comprehensive design, development, prototyping, and testing capabilities to help researchers and manufacturers meet the growing demand for these medical products. The initiative is set to foster new industry innovations and support academic pipelines for improved health outcomes.

**3. The Rise of Jabil (JBL): From Circuit Boards to AI Infrastructure Powerhouse**
- Source: FinancialContent | 20251222T150841 | Bullish | Relevance: 100%
- Jabil Inc. (NYSE: JBL) has transformed from a traditional contract manufacturer into a key player in global AI infrastructure and specialized healthcare ecosystems. This strategic pivot, marked by the sale of its Mobility business, has resulted in Jabil becoming a top performer in the S&P 500, with robust financial results driven by high-margin segments like AI and data centers. The company's focus on capital efficiency and engineering excellence under CEO Michael Dastoor positions it strongly in the evolving industrial technology sector.

**4. The Rise of Jabil (JBL): From Circuit Boards to AI Infrastructure Powerhouse**
- Source: FinancialContent | 20251222T095500 | Bullish | Relevance: 100%
- Jabil Inc. (NYSE: JBL) has undergone a significant transformation from a traditional contract manufacturer to a leading provider of AI infrastructure and specialized healthcare ecosystems. The company's strategic divestiture of its Mobility business in late 2023 allowed it to focus on higher-margin sectors, leading to a strong financial performance and its emergence as a top performer within the S&P 500. Jabil's success is driven by its innovative solutions in liquid cooling for AI data centers and its expansion into the regulated drug-delivery market, positioning it as a key player in the evolving industrial technology sector.

**5. Jim Cramer on Jabil: "You're Practically Getting This Quarter for Free"**
- Source: Finviz | 20251221T200813 | Bullish | Relevance: 100%
- Jim Cramer highlighted Jabil Inc. (NYSE: JBL) as a bullish pick due to its significant share buyback activity and successful business transformation from a low-multiple manufacturer to a design and product management service provider. Despite a sector sell-off impacting its stock post a strong earnings report, Cramer believes investors are essentially getting the most recent quarter "for free" because the stock is up 50% year-to-date. He also previously identified Jabil as a favorite, noting its consistently strong performance across various sectors like healthcare, autos, and electronics.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | JP Morgan | $270 | $260 | +4% |
| 2025-12-18 | Barclays | $283 | $267 | +6% |
| 2025-12-18 | UBS | $244 | $239 | +2% |
| 2025-12-10 | B of A Securiti | $262 | $255 | +3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | JP Morgan | main | Overweight |
| 2025-12-18 | Barclays | main | Overweight |
| 2025-12-18 | UBS | main | Neutral |
| 2025-12-10 | B of A Securiti | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 7 ($0.00M) |
| Sells | 50 ($12.50M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 12.3% (-0.1%)
- Blackrock Inc.: 9.0% (+2.1%)
- Texas Yale Capital C: 6.0% (-0.1%)
- State Street Corpora: 4.9% (+0.7%)
- Wellington Managemen: 4.1% (-30.7%)

### Key Risks

1. Heavy insider selling: $13M sold (50 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 4 raises (avg +4%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +5.2% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.91 indicates undervaluation relative to growth. Quality metrics strong (ROE 48%). Insider selling cluster ($12.5M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $24.5B |
| Beta | 1.26 |
| 52W Range | $108.66 - $237.14 |
| Short Interest | 4.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.91 |
| Forward P/E | 16.9 |
| Current P/E | 19.7 |
| YoY Growth | 16.5% |
| EPS Direction | RISING |

### Technicals

MRS_10 strengthening from -3.2% to 1.9% (+5.2% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.1pp (needs >3.0% for momentum thesis). MRS_5 at 2.8% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +SLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.93% (CS: 81) | Neutral |
| RSI_14 | 61.3 | Neutral |
| MACD Histogram | 0.47 | Bullish |
| vs SMA20 | 1.054x | Above |
| vs SMA50 | 1.083x | Above |
| vs SMA200 | 1.195x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $229.74
- **Stop Loss:** $210.30 (8.5% risk)
- **Target:** $249.18 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 61
- **Position Value:** $14,014.14
- **Portfolio %:** 14.01%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $2.73 | $2.85 | +4.4% |
| 2025Q3 | $2.95 | $3.29 | +11.7% |
| 2025Q2 | $2.32 | $2.55 | +9.8% |
| 2025Q1 | $1.83 | $1.94 | +6.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*